The global aplastic anemia market is expected to experience significant growth over the next decade, driven by a surge in research activities, the introduction of novel treatment options, and an increasing focus on improving patient outcomes. This market is projected to reach US$ 10.8 billion by 2034, with a CAGR of 4.3% from 2024 to 2034.